Status:
UNKNOWN
Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia
Lead Sponsor:
Indonesia University
Collaborating Sponsors:
Santen Pharmaceutical Co., Ltd.
Conditions:
Dry Eye Disease
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to determine the effectiveness of preventive therapy with diquafosol sodium 3% compared to sodium hyaluronate 0.1% to prevent dry eye disease in patient who will und...
Detailed Description
The general objective of this study is to determine the effectiveness of preventive therapy with diquafosol sodium 3% compared to sodium hyaluronate 0.1% for patient who will undergo cataract surgery....
Eligibility Criteria
Inclusion
- Cataract patients who will undergo phacoemulsification procedures and intraocular lens (IOL) implants
- Patients with dry eye disease
- Patients are willing to participate in the study and fill out informed consent
Exclusion
- Subjects with lacrimal gland or eyelid disorders (ptosis, blepharospasm, lagophthalmos, entropion, ectropion, and blepharitis)
- There are complications after cataract surgery
- Patients with a history of using topical medications / eye drops that are used routinely
- History of eye surgery in the last 6 months
- Serious ocular surface disorders (Sjögren syndrome, pemphigoid, chemical trauma)
- Using regular medication that trigger dry eye conditions (eg antihistamines, antidepressants, decongestants, anticholinergics) / allergy to diquafosol drugs
Key Trial Info
Start Date :
October 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06146881
Start Date
October 2 2022
End Date
March 15 2024
Last Update
November 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RSUPN Dr. Cipto Mangunkusumo
Jakarta Pusat, Jakarta Special Capital Region, Indonesia, 10430